p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses

Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.I. Ellenhorn, Don J. Diamond, Vincent Chung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers.

EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization for immunophenotyping, monitoring of p53MVA-induced immune response, and examination of PD1 checkpoint inhibition in vitro.

RESULTS: p53MVA immunization was well tolerated at both doses, with no adverse events above grade 2. CD4+ and CD8+ T cells showing enhanced recognition of a p53 overlapping peptide library were detectable after the first immunization, particularly in the CD8+ T-cell compartment (P=0.03). However, in most patients, this did not expand further with the second and third immunization. The frequency of PD1+ T cells detectable in patients' peripheral blood mononuclear cells (PBMC) was significantly higher than in healthy controls. Furthermore, the frequency of PD1+ CD8+ T cells showed an inverse correlation with the peak CD8+ p53 response (P=0.02) and antibody blockade of PD1 in vitro increased the p53 immune responses detected after the second or third immunizations. Induction of strong T-cell and antibody responses to the MVA backbone were also apparent.

CONCLUSION: p53MVA was well tolerated and induced robust CD8+ T-cell responses. Combination of p53MVA with immune checkpoint inhibition could help sustain immune responses and lead to enhanced clinical benefit.

Original languageEnglish
Pages (from-to)4459-4470
Number of pages12
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume20
Issue number17
DOIs
Publication statusPublished - Sep 1 2014
Externally publishedYes

Fingerprint

Immunization
T-Lymphocytes
Vaccinia
Neoplasms
Therapeutics
Peptide Library
Immunophenotyping
Gastrointestinal Neoplasms
Antibody Formation
Blood Cells
Vaccines
Antibodies
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. / Hardwick, Nicola R.; Carroll, Mary; Kaltcheva, Teodora; Qian, Dajun; Lim, Dean; Leong, Lucille; Chu, Peiguo; Kim, Joseph; Chao, Joseph; Fakih, Marwan; Yen, Yun; Espenschied, Jonathan; Ellenhorn, Joshua D.I.; Diamond, Don J.; Chung, Vincent.

In: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 20, No. 17, 01.09.2014, p. 4459-4470.

Research output: Contribution to journalArticle

Hardwick, NR, Carroll, M, Kaltcheva, T, Qian, D, Lim, D, Leong, L, Chu, P, Kim, J, Chao, J, Fakih, M, Yen, Y, Espenschied, J, Ellenhorn, JDI, Diamond, DJ & Chung, V 2014, 'p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 20, no. 17, pp. 4459-4470. https://doi.org/10.1158/1078-0432.CCR-13-3361
Hardwick, Nicola R. ; Carroll, Mary ; Kaltcheva, Teodora ; Qian, Dajun ; Lim, Dean ; Leong, Lucille ; Chu, Peiguo ; Kim, Joseph ; Chao, Joseph ; Fakih, Marwan ; Yen, Yun ; Espenschied, Jonathan ; Ellenhorn, Joshua D.I. ; Diamond, Don J. ; Chung, Vincent. / p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. In: Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 ; Vol. 20, No. 17. pp. 4459-4470.
@article{a1649afbc5bc499884128e1ad308f1cf,
title = "p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses",
abstract = "PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers.EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization for immunophenotyping, monitoring of p53MVA-induced immune response, and examination of PD1 checkpoint inhibition in vitro.RESULTS: p53MVA immunization was well tolerated at both doses, with no adverse events above grade 2. CD4+ and CD8+ T cells showing enhanced recognition of a p53 overlapping peptide library were detectable after the first immunization, particularly in the CD8+ T-cell compartment (P=0.03). However, in most patients, this did not expand further with the second and third immunization. The frequency of PD1+ T cells detectable in patients' peripheral blood mononuclear cells (PBMC) was significantly higher than in healthy controls. Furthermore, the frequency of PD1+ CD8+ T cells showed an inverse correlation with the peak CD8+ p53 response (P=0.02) and antibody blockade of PD1 in vitro increased the p53 immune responses detected after the second or third immunizations. Induction of strong T-cell and antibody responses to the MVA backbone were also apparent.CONCLUSION: p53MVA was well tolerated and induced robust CD8+ T-cell responses. Combination of p53MVA with immune checkpoint inhibition could help sustain immune responses and lead to enhanced clinical benefit.",
author = "Hardwick, {Nicola R.} and Mary Carroll and Teodora Kaltcheva and Dajun Qian and Dean Lim and Lucille Leong and Peiguo Chu and Joseph Kim and Joseph Chao and Marwan Fakih and Yun Yen and Jonathan Espenschied and Ellenhorn, {Joshua D.I.} and Diamond, {Don J.} and Vincent Chung",
year = "2014",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-13-3361",
language = "English",
volume = "20",
pages = "4459--4470",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses

AU - Hardwick, Nicola R.

AU - Carroll, Mary

AU - Kaltcheva, Teodora

AU - Qian, Dajun

AU - Lim, Dean

AU - Leong, Lucille

AU - Chu, Peiguo

AU - Kim, Joseph

AU - Chao, Joseph

AU - Fakih, Marwan

AU - Yen, Yun

AU - Espenschied, Jonathan

AU - Ellenhorn, Joshua D.I.

AU - Diamond, Don J.

AU - Chung, Vincent

PY - 2014/9/1

Y1 - 2014/9/1

N2 - PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers.EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization for immunophenotyping, monitoring of p53MVA-induced immune response, and examination of PD1 checkpoint inhibition in vitro.RESULTS: p53MVA immunization was well tolerated at both doses, with no adverse events above grade 2. CD4+ and CD8+ T cells showing enhanced recognition of a p53 overlapping peptide library were detectable after the first immunization, particularly in the CD8+ T-cell compartment (P=0.03). However, in most patients, this did not expand further with the second and third immunization. The frequency of PD1+ T cells detectable in patients' peripheral blood mononuclear cells (PBMC) was significantly higher than in healthy controls. Furthermore, the frequency of PD1+ CD8+ T cells showed an inverse correlation with the peak CD8+ p53 response (P=0.02) and antibody blockade of PD1 in vitro increased the p53 immune responses detected after the second or third immunizations. Induction of strong T-cell and antibody responses to the MVA backbone were also apparent.CONCLUSION: p53MVA was well tolerated and induced robust CD8+ T-cell responses. Combination of p53MVA with immune checkpoint inhibition could help sustain immune responses and lead to enhanced clinical benefit.

AB - PURPOSE: To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA) in patients with refractory gastrointestinal cancers.EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0×10(8) plaque-forming unit (pfu) p53MVA followed by nine patients at 5.6×10(8) pfu. Toxicity was classified using the NCI Common Toxicity Criteria and clinical responses were assessed by CT scan. Peripheral blood samples were collected pre- and post-immunization for immunophenotyping, monitoring of p53MVA-induced immune response, and examination of PD1 checkpoint inhibition in vitro.RESULTS: p53MVA immunization was well tolerated at both doses, with no adverse events above grade 2. CD4+ and CD8+ T cells showing enhanced recognition of a p53 overlapping peptide library were detectable after the first immunization, particularly in the CD8+ T-cell compartment (P=0.03). However, in most patients, this did not expand further with the second and third immunization. The frequency of PD1+ T cells detectable in patients' peripheral blood mononuclear cells (PBMC) was significantly higher than in healthy controls. Furthermore, the frequency of PD1+ CD8+ T cells showed an inverse correlation with the peak CD8+ p53 response (P=0.02) and antibody blockade of PD1 in vitro increased the p53 immune responses detected after the second or third immunizations. Induction of strong T-cell and antibody responses to the MVA backbone were also apparent.CONCLUSION: p53MVA was well tolerated and induced robust CD8+ T-cell responses. Combination of p53MVA with immune checkpoint inhibition could help sustain immune responses and lead to enhanced clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=84928965963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928965963&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-3361

DO - 10.1158/1078-0432.CCR-13-3361

M3 - Article

C2 - 24987057

AN - SCOPUS:84928965963

VL - 20

SP - 4459

EP - 4470

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -